FR22C1035I2 - Polypeptides à action prolongée et procédés de production et d'administration de ceux-ci - Google Patents

Polypeptides à action prolongée et procédés de production et d'administration de ceux-ci

Info

Publication number
FR22C1035I2
FR22C1035I2 FR22C1035C FR22C1035C FR22C1035I2 FR 22C1035 I2 FR22C1035 I2 FR 22C1035I2 FR 22C1035 C FR22C1035 C FR 22C1035C FR 22C1035 C FR22C1035 C FR 22C1035C FR 22C1035 I2 FR22C1035 I2 FR 22C1035I2
Authority
FR
France
Prior art keywords
administration
production
methods
long
acting polypeptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1035C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Original Assignee
Opko Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US14/059,134 external-priority patent/US20140113860A1/en
Priority claimed from US14/309,496 external-priority patent/US20150038413A1/en
Application filed by Opko Biologics Ltd filed Critical Opko Biologics Ltd
Publication of FR22C1035I1 publication Critical patent/FR22C1035I1/fr
Application granted granted Critical
Publication of FR22C1035I2 publication Critical patent/FR22C1035I2/fr
Active legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/59Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/24Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/06Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/61Growth hormone [GH], i.e. somatotropin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
FR22C1035C 2013-10-21 2022-07-13 Polypeptides à action prolongée et procédés de production et d'administration de ceux-ci Active FR22C1035I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14/059,134 US20140113860A1 (en) 2006-02-03 2013-10-21 Long-acting polypeptides and methods of producing and administering same
US14/309,496 US20150038413A1 (en) 2006-02-03 2014-06-19 Long-acting polypeptides and methods of producing and administering same
PCT/IL2014/050910 WO2015059695A1 (en) 2013-10-21 2014-10-21 Long-acting polypeptides and methods of producing and administering same

Publications (2)

Publication Number Publication Date
FR22C1035I1 FR22C1035I1 (fr) 2022-09-09
FR22C1035I2 true FR22C1035I2 (fr) 2024-02-16

Family

ID=52992360

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1035C Active FR22C1035I2 (fr) 2013-10-21 2022-07-13 Polypeptides à action prolongée et procédés de production et d'administration de ceux-ci

Country Status (20)

Country Link
EP (2) EP3060239B1 (ko)
JP (3) JP6640720B2 (ko)
KR (4) KR20240110069A (ko)
CN (1) CN106163543A (ko)
AU (3) AU2014338575B2 (ko)
CA (1) CA2928269C (ko)
DK (1) DK3060239T3 (ko)
ES (1) ES2811068T3 (ko)
FR (1) FR22C1035I2 (ko)
HR (1) HRP20201114T1 (ko)
HU (2) HUE050002T2 (ko)
IL (1) IL297219B2 (ko)
MX (2) MX2016005227A (ko)
NL (1) NL301170I2 (ko)
PL (1) PL3060239T3 (ko)
PT (1) PT3060239T (ko)
RU (1) RU2746943C2 (ko)
SI (1) SI3060239T1 (ko)
TW (5) TWI720939B (ko)
WO (1) WO2015059695A1 (ko)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015059695A1 (en) 2013-10-21 2015-04-30 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
JOP20190019A1 (ar) * 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
CN109942717A (zh) * 2019-04-24 2019-06-28 上海延立药业有限公司 一种长效重组人促卵泡激素及其制备方法和应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
DE3421468A1 (de) 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
ATE141646T1 (de) 1986-04-09 1996-09-15 Genzyme Corp Genetisch transformierte tiere, die ein gewünschtes protein in milch absondern
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
WO1989010756A1 (en) 1988-05-06 1989-11-16 Toray Industries, Inc. STABLE INTERFERON beta COMPOSITION
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
ATE148171T1 (de) 1989-02-21 1997-02-15 Univ Washington Modifizierte formen von fortpflanzungshormonen
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5541110A (en) 1994-05-17 1996-07-30 Bristol-Myers Squibb Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
US7553941B2 (en) * 2006-02-03 2009-06-30 Modigene Inc Long-acting polypeptides and methods of producing same
US8450269B2 (en) * 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
US8048849B2 (en) * 2006-02-03 2011-11-01 Modigene, Inc. Long-acting polypeptides and methods of producing same
US8476234B2 (en) * 2006-02-03 2013-07-02 Prolor Biotech Inc. Long-acting coagulation factors and methods of producing same
US8304386B2 (en) * 2006-02-03 2012-11-06 Prolor Biotech, Inc. Long-acting growth hormone and methods of producing same
US20140113860A1 (en) 2006-02-03 2014-04-24 Prolor Biotech Ltd. Long-acting polypeptides and methods of producing and administering same
US8946155B2 (en) * 2006-02-03 2015-02-03 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same
DE102007006189B4 (de) * 2007-02-07 2009-07-30 Isotopen Technologien München AG Vorrichtung zum Befüllen eines medizinischen Instruments mit einer radioaktiven Substanz und Verfahren
WO2015059695A1 (en) 2013-10-21 2015-04-30 Opko Biologics Ltd. Long-acting polypeptides and methods of producing and administering same

Also Published As

Publication number Publication date
KR102444140B1 (ko) 2022-09-15
HRP20201114T1 (hr) 2020-10-30
HUS2200014I1 (hu) 2022-05-28
TW201536327A (zh) 2015-10-01
NL301170I2 (nl) 2022-06-16
NL301170I1 (nl) 2022-04-29
CA2928269A1 (en) 2015-04-30
KR20160068969A (ko) 2016-06-15
RU2021110927A3 (ko) 2021-12-08
TW202120120A (zh) 2021-06-01
KR20240110069A (ko) 2024-07-12
TW201536312A (zh) 2015-10-01
WO2015059695A1 (en) 2015-04-30
IL297219B1 (en) 2023-10-01
EP3763733A1 (en) 2021-01-13
JP7051797B2 (ja) 2022-04-11
TWI720940B (zh) 2021-03-11
TWI720939B (zh) 2021-03-11
SI3060239T1 (sl) 2020-10-30
MX2021003908A (es) 2021-06-23
AU2022246472A1 (en) 2022-11-10
TW201536313A (zh) 2015-10-01
AU2020200874A1 (en) 2020-02-27
CA2928269C (en) 2023-03-14
TW202317176A (zh) 2023-05-01
JP2022088521A (ja) 2022-06-14
KR20210118490A (ko) 2021-09-30
AU2014338575A1 (en) 2016-06-02
PT3060239T (pt) 2020-08-26
RU2021110927A (ru) 2021-05-21
TWI777407B (zh) 2022-09-11
RU2016119565A (ru) 2018-11-02
EP3060239A4 (en) 2017-05-31
EP3060239B1 (en) 2020-05-13
KR20220130254A (ko) 2022-09-26
ES2811068T3 (es) 2021-03-10
FR22C1035I1 (fr) 2022-09-09
RU2016119565A3 (ko) 2019-01-22
JP2016535015A (ja) 2016-11-10
HUE050002T2 (hu) 2020-11-30
AU2014338575B2 (en) 2019-11-07
JP2020073541A (ja) 2020-05-14
MX2016005227A (es) 2016-08-12
IL297219A (en) 2022-12-01
JP6640720B2 (ja) 2020-02-05
PL3060239T3 (pl) 2020-11-02
CN106163543A (zh) 2016-11-23
IL297219B2 (en) 2024-02-01
EP3060239A1 (en) 2016-08-31
JP7445695B2 (ja) 2024-03-07
RU2746943C2 (ru) 2021-04-22
DK3060239T3 (da) 2020-08-03

Similar Documents

Publication Publication Date Title
MA49715A (fr) Oligomères et conjugués d'oligomères
DK2983721T4 (da) Terapeutiske indgivelsesvesikler
DK3022707T3 (da) Systemer og fremgangsmåder til at monitorere bevægelse af sygdomsfelt
BR112015001211A2 (pt) novos ácidos 5-aminotetra-hidroquinolina-2-carboxílicos e sua utilização
DK2968443T3 (da) Hepcidinanaloger og anvendelser deraf
FR22C1035I2 (fr) Polypeptides à action prolongée et procédés de production et d'administration de ceux-ci
DK2968221T3 (da) Farmaceutisk sammensætning af s-ketaminhydrochlorid
FI20135915A (fi) Parannettu gyroskooppirakenne ja gyroskooppi
BR112013033149A2 (pt) peça de vestuário e método de sua produção
DK3079655T3 (da) Inhalerbare lægemidler
FR3004739B3 (fr) Ensemble d'ancrage
DK2832236T4 (da) Fremgangsmåde til fremstilling af hydrolyseret keratinholdigt materiale
BR112014015220A8 (pt) produto de gesso anti-abaulamento e método de fabricação
DK2964193T3 (da) Lægemidler til oral indgivelse
DK3228313T3 (da) Doseringsformer og terapeutiske anvendelser af L-4-chlorkynurenin
GB201518061D0 (en) Method of determining degree of modified potency of bipathic medicament
DK3003401T3 (da) Farmaceutisk præparat
GB201307082D0 (en) Pharmaceutical composition comprising 15-HETrE and methods of using the same
MA42130A (fr) Combinaisons d'opioïdes et de n-acyléthanolamines
DK2897588T3 (da) Inhalerbart lægemiddel
FI20116234A (fi) Menetelmä alusmateriaalin valmistamiseksi sekä alusmateriaali
MA45326A (fr) Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
CO6930059A1 (es) Formulaciones farmacéuticas y proceso de producción de formulaciones farmacéuticas
IL245273A0 (en) Long-acting polypeptides and methods for their preparation and administration
FR3025545B1 (fr) L'aligneur d'agglos et de briques